These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 34751775)

  • 1. Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
    Nguyen D; Xiao J; Simmonds P; Lamikanra A; Odon V; Ratcliff J; Townsend A; Roberts DJ; Harvala H
    J Infect Dis; 2022 Mar; 225(6):971-976. PubMed ID: 34751775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction.
    Lamikanra A; Nguyen D; Simmonds P; Williams S; Bentley EM; Rowe C; Otter AD; Brooks T; Gilmour K; Mai A; Dadhra J; Csatari M; Ziyenge S; Oliveira M; Ploeg R; Tsang P; Zambon M; Gopal R; Xiao JH; Townsend A; Roberts D; Harvala H
    Transfusion; 2021 Oct; 61(10):2837-2843. PubMed ID: 34342366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
    Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
    Viruses; 2021 May; 13(5):. PubMed ID: 34065987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
    Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.
    Salazar E; Kuchipudi SV; Christensen PA; Eagar T; Yi X; Zhao P; Jin Z; Long SW; Olsen RJ; Chen J; Castillo B; Leveque C; Towers D; Lavinder J; Gollihar J; Cardona J; Ippolito G; Nissly R; Bird I; Greenawalt D; Rossi RM; Gontu A; Srinivasan S; Poojary I; Cattadori IM; Hudson PJ; Josleyn NM; Prugar L; Huie K; Herbert A; Bernard DW; Dye JM; Kapur V; Musser JM
    J Clin Invest; 2020 Dec; 130(12):6728-6738. PubMed ID: 32910806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma.
    Fenwick C; Turelli P; Pellaton C; Farina A; Campos J; Raclot C; Pojer F; Cagno V; Nusslé SG; D'Acremont V; Fehr J; Puhan M; Pantaleo G; Trono D
    Sci Transl Med; 2021 Aug; 13(605):. PubMed ID: 34257144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.
    Hirani R; Hoad V; Gosbell IB; Irving DO
    Transfusion; 2022 Feb; 62(2):292-297. PubMed ID: 34936102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.
    Drews SJ; Devine DV; McManus J; Mendoza E; Manguiat K; Wood H; Girardin R; Dupuis A; McDonough K; Drebot M
    Transfusion; 2021 May; 61(5):1440-1446. PubMed ID: 33734448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods.
    Banga Ndzouboukou JL; Zhang YD; Fan XL
    Curr Med Sci; 2021 Dec; 41(6):1052-1064. PubMed ID: 34935114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
    Goodhue Meyer E; Simmons G; Grebe E; Gannett M; Franz S; Darst O; Di Germanio C; Stone M; Contestable P; Prichard A; Reik R; Vassallo R; Young P; Busch MP; Williamson P; Dumont LJ
    Transfusion; 2021 Apr; 61(4):1160-1170. PubMed ID: 33554362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Antibody Responses in COVID-19 Convalescent Sera.
    Lee WT; Girardin RC; Dupuis AP; Kulas KE; Payne AF; Wong SJ; Arinsburg S; Nguyen FT; Mendu DR; Firpo-Betancourt A; Jhang J; Wajnberg A; Krammer F; Cordon-Cardo C; Amler S; Montecalvo M; Hutton B; Taylor J; McDonough KA
    J Infect Dis; 2021 Jan; 223(1):47-55. PubMed ID: 33104179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
    Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
    J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.